MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors

 MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors

PR Newswire

SAN DIEGO, June 11, 2013

SAN DIEGO, June 11, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today the appointment of Nick Glover, Ph.D., to its Board of
Directors. Dr. Glover was most recently President and Chief Executive Officer
of YM BioSciences, an oncology drug development company acquired by Gilead
Sciences for $510 million in February 2013. The appointment of Dr. Glover
increases MEI Pharma's board to seven members, including six independent
directors.

(Logo:http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

"Dr. Glover is a natural fit to round out our Board of Directors, adding a
wealth of relevant strategic and operational knowledge," said Daniel P. Gold,
Ph.D., President and Chief Executive Officer of MEI Pharma. "In addition to
firsthand experience leading an emerging hematology drug development company,
Nick has an extensive background in business development and strong
relationships within the life science investment community. We look forward to
the benefit of his experience as we execute multiple Phase II clinical trials
of Pracinostat in the months ahead and formulate strategies for maximizing its
value."

Dr. Glover served as President and Chief Executive Officer of YM BioSciences
from November 2010 until the completion of its acquisition by Gilead. YM's
lead drug candidate, CYT387, was an orally administered JAK inhibitor being
developed for the treatment of myelofibrosis. Previously, Dr. Glover was
President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical
company involved in the discovery and development of monoclonal antibody-based
technologies for the treatment of cancer. Prior to joining Viventia, he was an
investment manager at MDS Capital, a life sciences venture capital firm. Dr.
Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia,
U.K., and a Ph.D. in Chemistry from Simon Fraser University, Canada.

"I am pleased to be joining the board of MEI Pharma at such an exciting time,"
said Dr. Glover. "The Company has a very promising lead drug candidate,
Pracinostat, which has the potential to be both clinically and commercially
differentiated. In addition, MEI Pharma is led by an excellent team, and I
look forward to working with management and the board to assist in the
Company's advancement."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral histone
deacetylase (HDAC) inhibitor being developed for advanced hematologic
malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). Results from a pilot Phase II clinical trial of Pracinostat in
combination with azacitidine in patients with advanced MDS were presented at
the American Society of Hematology Annual Meeting in December 2012 showing an
overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company
plans to initiate a randomized, placebo-controlled Phase II trial of
Pracinostat in combination with azacitidine in patients with MDS in June 2013.
In addition, MEI Pharma is developing two drug candidates derived from its
isoflavone-based technology platform, ME-143 and ME-344. For more information,
go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, (858) 792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.